Diabetes drugs would be subject to more stringent safety standards that could cost manufacturers millions of dollars, under recommendations made Wednesday by a government panel.
The number of Americans with diabetes has grown to about 24 million people, or roughly 8 percent of the U.S. population, the government said Tuesday.
Aggressively treating diabetes does not prevent heart problems and deaths any better than standard treatment for lowering blood sugar, Australian researchers reported recently.
The survey of nearly 800,000 people is the first extensive look at the overlap between the two conditions, said Dr. John Klippel, president of the Arthritis Foundation
Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths
America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."
Cherie Cruse was devastated when she learned in 2003 that her 4-year-old son Andrew had juvenile diabetes.
Diabetes is the fifth-leading killer of Americans, according to the American Diabetes Association. A sobering two out of three people with type I or type II diabetes will die from a heart attack or stroke -- the combined leading causes of death among diabetics.
When I was 7 years old, my mom took me to the doctor because I had lost a lot of weight, despite a voracious appetite.
Diabetes is a disease in which the body either doesn't produce insulin, or it doesn't properly use insulin, or both. Insulin is a hormone produced by the pancreas that metabolizes glucose, which is the source of energy for cells in the body.
Diabetes drugs would be subject to more stringent safety standards that could cost manufacturers millions of dollars, under recommendations made Wednesday by a government panel.
The number of Americans with diabetes has grown to about 24 million people, or roughly 8 percent of the U.S. population, the government said Tuesday.
Aggressively treating diabetes does not prevent heart problems and deaths any better than standard treatment for lowering blood sugar, Australian researchers reported recently.
The survey of nearly 800,000 people is the first extensive look at the overlap between the two conditions, said Dr. John Klippel, president of the Arthritis Foundation
Insulin pumps are used by tens of thousands of teenagers worldwide with Type 1 diabetes, but they can be risky and have been linked to injuries and even deaths
America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."
Cherie Cruse was devastated when she learned in 2003 that her 4-year-old son Andrew had juvenile diabetes.
Diabetes is the fifth-leading killer of Americans, according to the American Diabetes Association. A sobering two out of three people with type I or type II diabetes will die from a heart attack or stroke -- the combined leading causes of death among diabetics.
When I was 7 years old, my mom took me to the doctor because I had lost a lot of weight, despite a voracious appetite.
Diabetes is a disease in which the body either doesn't produce insulin, or it doesn't properly use insulin, or both. Insulin is a hormone produced by the pancreas that metabolizes glucose, which is the source of energy for cells in the body.
Until a few years ago, kids got just one kind of diabetes, type I, an autoimmune disease in which the body doesn't produce enough insulin.
Did you know that most people who develop type II diabetes have a potentially dangerous condition called prediabetes for five to 10 years before their diagnosis?
Last winter our 11-month-old son Jake had the flu, we thought. My husband, Matt, and I had just gotten over it, and Jake was vomiting and acting lethargic.
Q: I'm 28 and diabetic. Now my husband and I would like to have a baby. Is there anything I should worry about because of my condition?
New research shows that insulin plays a key role in the brain -- and in the onset of Alzheimer's disease, prompting some researchers to call it "type 3" diabetes
Sometimes less is more. But when it comes to exercise for diabetics, researchers find, the more you do, the better it is
A new report says gestational diabetes is strongly linked to childhood obesity -- but there's a lot you can do to treat the condition
Pharmacy-benefits manager Medco Health Solutions Inc. said Tuesday it has agreed to buy PolyMedica Corp. for $1.5 billion, in a move to expand its diabetes care services.
The FDA said on Tuesday that GlaxoSmithKline and Takeda agreed to strengthen heart failure warnings on their diabetes drugs, Avandia and Actos.
Are you overweight? Diabetic? A new study suggests that maybe your bones are to blame
GlaxoSmithKline's stock rose nearly 4 percent on Tuesday, the day after FDA advisors voted to keep its diabetes drug Avandia on the market.
Food and Drug Administration panelists voted Monday that GlaxoSmithKline's diabetes drug Avandia should remain on the market, despite an analysis showing links to increased risk of heart attack.
GlaxoSmithKline is getting ready for a face-to-face with the FDA about its diabetes drug Avandia, which has been on the hot seat since a study blamed the drug for increasing the risk of heart attack.
As the nation's biggest diabetes conference wrapped up Tuesday, Bristol-Myers Squibb, AstraZeneca and Novo Nordisk emerged as drugmakers-to-watch with the most late-stage experimental diabetes drugs.
Debate over the heart attack risk associated with the GlaxoSmithKline diabetes drug Avandia took center stage Monday at the annual meeting of the American Diabetes Association.
Bristol and AstraZeneca reported Monday the most advanced late-stage studies for their experimental drug saxagliptin, showing it helped diabetics control their blood-sugar levels.
Bristol-Myers Squibb and AstraZeneca are working on a new type of diabetes drug, and early-stage test results in humans have showed that the experimental drug, called dapagliflozin, could control blood-sugar levels in diabetics and appears to be safe.
Early-stage studies in mice have shown that adult blood could be a richer source of insulin-creating stem cells than fertilized eggs, according to Dr. Yong Zhao, assistant professor at the University of Illinois.
Diabetics taking the blood-sugar drug Byetta had about one-sixth the risk of hypoglycemia compared to those taking insulin, according to study results from Byetta-makers Amylin and Lilly.
Merck's new drug Januvia controls blood-sugar in two-thirds of diabetics when combined with the drug metformin, the company said Saturday.
Cholesterol-lowering statins - which include the world's top-selling drug, Lipitor - and other drugs called fibrates can lower the risk of developing a common form of nerve damage in diabetics that often results in amputations, according to study results unveiled Friday.
A year before turning 50, Michele Thomas learned she had type 1 diabetes, a condition that used to be associated mainly with children.
GlaxoSmithKline PLC revealed Thursday that the U.S. Food and Drug Administration has declined to grant a priority review to its experimental cancer vaccine Cervarix
(CHICAGO)--Diabetic children who spent the most time glued to the TV had a tougher time controlling their blood sugar, according to a Norwegian study that illustrates yet another downside of too much television.The findings, based on a study of children with Type 1 diabetes, lend support to the American Academy of Pediatrics' advice that children watch no more than two hours of TV daily, said lead author Dr. Hanna Margeirsdottir of the University of Oslo.Type 1 diabetes is the less common form of the disease and used to be called juvenile diabetes. It is not related to obesity and is caused when the body cannot make insulin, which converts sugar from food into energy. People with Type 1 must take insulin daily and regulate their blood-sugar levels.Snacking and overeating can increase blood-sugar levels; physical activity can lower them. While TV-viewing is often accompanied by snacking, the researchers didn't examine diet or physical activity.The study results "suggest that encouraging children with Type
America's "epidemic of diabetes" could cause spending on drugs for that disease to soar up to 70 percent through 2009, according to the drug benefit manager Medco Health Solutions Inc.
As a baby boomer, you're probably making the best money of your career with little time for your health. But as you get older, your well-being gets more valuable. Money Magazine offers a few tips on how to take care of your aging self.
CNN medical correspondent Judy Fortin spoke with endocrinologist Dr. Bruce Bode of Atlanta Diabetes Associates about the differences and similarities between the two types of diabetes.
Government regulators are expected to decide by Friday whether to approve a new diabetes treatment from Merck that could add hundreds of millions of dollars in annual sales to its Januvia medication.
1. Cell-Phone Giants Start Courting Coders
More than 50 million people in the United States may be ticking metabolic time bombs. Many are young. Most have no clue that they are on the verge of developing a potentially devastating disease. They are prediabetics and their numbers are growing.
If you haven't heard of resveratrol, you're probably too young to have had the experience of gazing into the bathroom mirror in the morning and thinking, Damm." Resveratrol is the ingredient in re...
The sales pitches are irresistible: "Lose 2 Pounds a Day!" "Burn Fat Round the Clock!" "Learn the Amazing Weight-Loss Secret of Hollywood's Sex Symbols!" OK, maybe that's pushing it. But if diet pills could give you Eva Longoria's body, would you bother with the salads and stair-climbing?
As Big Pharma's pipeline for blockbuster drugs slows, med tech giants are helping to fill the gap with devices that treat everything from migraines to severe depression.
If you haven't heard of resveratrol, you're probably too young to have had the experience of gazing in the bathroom mirror in the morning and thinking, "damn."
Novartis could be the hottest drug giant in 2007, analysts say, with Schering-Plough and Eli Lilly & Co. not far behind.
Diabetes is sweeping through America like a wildfire, afflicting nearly 21 million Americans and fueling an estimated $20 billion industry for treatment.
After a rough couple of years dealing with patent expirations and the often frustrating hunt for new products, drug industry executives would love nothing better than an oracle to predict what products in their labs will become the big blockbuster drugs over the next few years.
Eli Lilly & Co. could have a rough time dealing with recent allegations that it concealed risks about its top-selling drug Zyprexa.
Drug giant Eli Lilly has engaged in a decade-long effort to play down the health risks of its top-selling medication, the schizophrenia drug Zyprexa, The New York Times reported in Sunday editions.
Diabetics are holding their breath, and that may not be good news for the Pfizer, the world's biggest drugmaker.
European regulators approved Byetta, a diabetes drug from Eli Lilly & Co. and Amylin Pharmaceuticals, the companies announced Tuesday.
Merck & Co. said Monday that its arthritis painkiller Arcoxia does not increase the risk of heart attacks, in a study underscoring the difference between this drug and its withdrawn-from-the-market blockbuster Vioxx.
The biotech Amylin is testing what could be the next blockbuster in the $40 billion market for weight loss products, or the treatment could just be a big fat flop.
The FDA has approved Merck's diabetes drug Januvia, the drug manufacturer said.
Confession time: My husband has actually uttered the words "I'd rather take a nap than have sex." Is our marriage on the rocks? No, like 75 percent of adults, our problem is sleep -- he has insomnia; I snore.
Fortune interviews Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited:
Merck announced Thursday that its experimental diabetes drug Januvia significantly lowers blood-sugar level when taken with another drug.
Novo Nordisk has sued Pfizer, alleging that the new product Exubera violates patents on inhalable insulin for diabetics.
Merck and Novartis both released studies on experimental diabetes drugs Tuesday, signaling an imminent market face-off between potential blockbusters.
An experimental drug from Novartis can reduce blood-sugar levels in diabetics when combined with the Takeda drug Actos, according to late-stage studies released Tuesday.
An experimental drug from Eli Lilly & Co. reduces the risk of vision loss in diabetics, who often suffer declining eyesight, according to studies released Sunday.
The use of antidepressants appears to increase the onset of diabetes in some high-risk individuals, according to a government-funded study announced Saturday.
Exubera, the first form of inhalable insulin to enter the market, is just as effective for diabetics as injectable insulin, according to a study released Saturday by Pfizer.
In its face-off with Novartis over the multi-billion dollar diabetes market, Merck revealed a study Saturday showing that its experimental drug Januvia slashed the risk of hypoglycemia more than sixfold while matching a generic drug's ability to reduce blood-sugar level.
Merck and Schering-Plough fired a shot across Pfizer's bow in the battle for control of the lucrative $25 billion cholesterol market with a new study saying their product is better for diabetics.
Eli Lilly & Co. and Amylin, makers of the diabetes treatment Byetta, reported Saturday that a more convenient-to-use but experimental version of the drug successfully reduces blood-sugar levels.
The drug giants Merck and Novartis could soon be locking horns for dominance in the multibillion-dollar diabetes sector.
JUDGING BY THE HEADLINES, IT WOULD BE EASY TO THINK that Big Pharma is on the brink of collapse. In 2006 the industry is poised to lose more than $23 billion in sales to generic competitors, its wo...
The FDA approved Pfizer's Exubera, the first inhalable form of insulin for diabetics.
Exubera, Pfizer's experimental inhalant for treating diabetes, has not been approved by the FDA, but a public relations blunder by the company's CEO had many believing otherwise Friday.
A few months ago, I was interviewing a principal at a Chicago, Illinois, public elementary school, when from outside her office came the sounds of a child coughing.
Arena Pharmaceuticals stock surged as much as 23 percent Wednesday after the California biotech announced study results for its experimental weight loss drug.
Caution, caution
As a child, John Karaffa had a single driving ambition that became the central theme of his life -- he wanted to help people.
A London-based design student has created a glucose-monitoring device that he hopes will make life easier for diabetics.
An experimental drug from Sanofi-Aventis has been shown to have multiple benefits in treating heart disease and diabetes, the big French drugmaker announced Wednesday.
Abbott's drug levosimendan failed to significantly reduce the death rate in patients with heart failure, according to researchers and the company, which announced study results Wednesday at the American Heart Association conference here.
Tricor, a cholesterol drug from Abbott Laboratories, reduced non-fatal heart attacks in diabetics by 24 percent, according to a study unveiled Monday at the American Heart Association conference.
Abbott Laboratories, one of America's largest drugmakers, plans to reveal data showing that use of Tricor in type 2 diabetics could prevent heart disease, the company said.
As Dr. Steven E. Nissen methodically ticks off the risks of what seemed like a highly promising experimental diabetes drug -- heart attacks, strokes, and death -- he is completely in his element.
If the future of Big Pharma can be read in its pipelines, Eli Lilly & Co. and Sanofi-Aventis are among the few bright spots, analysts say -- but investors should also look at Pfizer, which is experimenting with a drug combo that could outsell all others.
CNN.com users share their experiences of how technology is changing our lives.
A mother accused of killer her daughter by withholding her insulin, sat on a couch watching TV with a beer in front of her as her daughter lay sick in bed, the girl's best friend testified Thursday.
Drug safety made headlines in the major medical journals this week when noted Cleveland Clinic cardiologists came up with a disturbing analysis about a new diabetes drug that is just a hair away from approval by the Food and Drug Administration.
Drug giants Bristol-Myers Squibb and Merck & Co., Inc. said the FDA issued an approvable letter for Pargluva, a big step toward getting the potential diabetes drug on the market, but leading analysts are no longer seeing the drug as a potential blockbuster.
The "art" of medicine -- a term that doctors often fall back on when the "science" of medicine is open to interpretation -- was illustrated by studies in the leading medical journals this week.
An FDA panel of experts voted Friday in favor of muraglitazar, a once-a-day pill meant to lower blood sugar and reduce the risk of heart disease.
FDA advisors voted Thursday in favor of Exubera, the first form of inhalable insulin, a step that could lead to approval by the regulatory agency.
An FDA advisory panel voted unanimously in favor of abatacept, a Bristol-Myers Squibb treatment for rheumatoid arthritis, a move that often precedes FDA approval.
Next week, millions of diabetics will find out what the government's experts think about inhalable insulin, a treatment that could let them throw away their needles.
On Monday the Food and Drug Administration approved a combination pill for diabetes from Takeda Pharmaceuticals North America, a subsidiary of the Japanese drug manufacturer.
Bristol-Myers Squibb faces votes by FDA advisory panels on two key drugs in its pipeline, decisions that could affect the company's financial future for years to come.
Lisa Altman couldn't sleep. On a Thursday night in late July, her husband was traveling, and the novel she'd been reading was keeping her awake. So At 5 A.M. she gave up, flipped on the television,...
Gender-specific tests
NEW YORK (CNN/Money) - Sanofi-Aventis' diabetes drug Lantus has flourished in the lucrative industry for insulin products, and according to analysts, it will continue to do so despite two competing drugs which have recently entered the market.
Two blockbuster diabetes drugs, Actos and Avandia, have locked horns for years in a very lucrative market but an impending shift in corporate partnerships and the introduction of new blockbusters could tilt the balance, industry analysts said.
A landmark finding a decade ago that sharply enhanced the lives of insulin-dependent diabetics now turns out to be much more beneficial than anyone suspected.
A new drug from Sanofi-Aventis is a weight loss pill and a diabetes treatment at the same time, and could treat millions of Americans if approved by the Food and Drug Administration. Separate studies have shown the drug may be effective at helping smokers quit the habit.
Merck and Bristol-Myers Squibb, both facing losses on two of their most profitable blockbusters, are partnering to try and launch a pill that has multiple uses in treating diabetes.
San Diego (CNN/Money) - Diabetics could spend years waiting to inhale.
| Most Viewed | Most Emailed | Top Searches |
Video
